Technology in Cancer Research & Treatment (Apr 2024)

The Role of microRNAs in Hepatocellular Cancer: A Narrative Review Focused on Tumor Microenvironment and Drug Resistance

  • Ali Tavakoli Pirzaman MD,
  • Ali Alishah MS,
  • Bahareh Babajani MS,
  • Pouyan Ebrahimi MD,
  • Seyyed Ali Sheikhi MS,
  • Farhad Moosaei MS,
  • Amirhossein Salarfar MS,
  • Shahrbanoo Doostmohamadian MS,
  • Sohrab Kazemi PhD

DOI
https://doi.org/10.1177/15330338241239188
Journal volume & issue
Vol. 23

Abstract

Read online

Globally, hepatic cancer ranks fourth in terms of cancer-related mortality and is the sixth most frequent kind of cancer. Around 80% of liver cancers are hepatocellular carcinomas (HCC), which are the leading cause of cancer death. It is well known that HCC may develop resistance to the available chemotherapy treatments very fast. One of the biggest obstacles in providing cancer patients with appropriate care is drug resistance. According to reports, more than 90% of cancer-specific fatalities are caused by treatment resistance. By binding to the 3'-untranslated region of target messenger RNAs (mRNAs), microRNAs (miRNAs), a group of noncoding RNAs which are around 17 to 25 nucleotides long, regulate target gene expression. Moreover, they play role in the control of signaling pathways, cell proliferation, and cell death. As a result, miRNAs play an important role in the microenvironment of HCC by changing immune phenotypes, hypoxic conditions, and acidification, as well as angiogenesis and extracellular matrix components. Moreover, changes in miRNA levels in HCC can effectively resist cancer cells to chemotherapy by affecting various cellular processes such as autophagy, apoptosis, and membrane transporter activity. In the current work, we narratively reviewed the role of miRNAs in HCC, with a special focus on tumor microenvironment and drug resistance.